BHC
NBIX icon

Bull Harbor Capital’s Neurocrine Biosciences NBIX Stock Holding History

Bull Harbor Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Sell
8,489
-724
-8% -$107K 0.28% 85
2026
Q1 		$1.21M Buy
+9,213
New +$1.22M 0.33% 85

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bull Harbor Capital's NBIX Position: Q2 2026 in Review

Bull Harbor Capital reduced its Neurocrine Biosciences (NBIX) stake by 7.9% in Q2 2026, selling an estimated $107K and leaving 8,489 shares worth $1.43M. The position accounts for 0.28% of the portfolio, ranked #85.

Bull Harbor Capital first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bull Harbor Capital held 8,489 shares of Neurocrine Biosciences worth $1.43M as of Q2 2026.
  • Bull Harbor Capital sold 724 Neurocrine Biosciences shares in Q2 2026, an estimated $107K.
  • Neurocrine Biosciences made up 0.28% of Bull Harbor Capital's portfolio in Q2 2026, its #85 holding.
  • Bull Harbor Capital first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bull Harbor Capital's 13F filing for Q2 2026, filed 10 Aug 2026.